Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation.
A total of 16 patients with progressive CNS gliomas who had previously received maximal radiation therapy and chemotherapy were treated on a phase II study using high-dose etoposide with autologous bone marrow transplantation to assure hematopoietic recovery. Three patients (19%) responded with both improved neurological status and decreased mass on computerized tomographic scan. Median survival for all treated patients was 4 months with the three responders living 9, 10, and 54+ months.
D000293:Adolescent; D000328:Adult; D001254:Astrocytoma / Q000188:drug therapy*; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005909:Glioblastoma / Q000188:drug therapy*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged
D005047:Etoposide